Evidence map›Paper›PMID 28527342›Full record

ArticleVirology2017

Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART.

Nadejda Beliakova-Bethell, Marjan Hezareh, Joseph K Wong, Matthew C Strain, Mary K Lewinski, Douglas D Richman, Celsa A Spina

Open access · greenAbstract readComparative Study
In one paragraph

Article in Virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nadejda Beliakova-BethellVA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA 92161, USA; University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA.
Marjan HezarehUniversity of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA.
Joseph K WongVA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA 92161, USA; University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA.
Matthew C StrainUniversity of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA.
Mary K LewinskiVA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA 92161, USA; University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA.
Douglas D RichmanVA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA 92161, USA; University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA.
Celsa A SpinaVA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA 92161, USA; University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA. Electronic address: cspina@ucsd.edu.
University of California San Diego · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Using NK Cells to eliminate the latent HIV reservoirU19AI096113 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOELK, CHRISTOPHER H · 2011 to 2015
$39.5M
Southern California Primary Infection ProgramU01AI043638 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 1998 to 2010
$21.3M
WOMEN'S HEALTH AGENDAU01AI027670 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 1988 to 2006
$13.7M
IN VIVO HIV LATENCY REVEALED BY POTENT ANTIVIRAL THERAPYR01AI043752 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI WONG, JOSEPH K. · 1999 to 2002
$759k
Control of Latent/Persistent HIV Infection in Primary CD4 T CellsI01BX001160 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI SPINA, CELSA A · 2011 to 2014
–
BLRD VA I01 BX001160NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI043752NIAID NIH HHS U01 AI027670NIAID NIH HHS U01 AI043638NIAID NIH HHS U19 AI096113
6 · The paper itself

Abstract

Quantification of cell-associated replication-competent HIV, in blood samples from patients with undetectable plasma viremia, requires specialized culture conditions that include exogenous pan T cell stimulation. Different research groups have used several stimuli for this purpose; however, the relative efficacies of these T cell stimuli to induce productive HIV replication from latently infected cells ex vivo have not been systematically evaluated. To this end, we compared four commonly used T cell stimuli: 1) irradiated allogeneic cells plus phytohaemagglutinin (PHA); 2) PHA alone; 3) phorbol myristate acetate plus Ionomycin; and 4) immobilized αCD3 plus αCD28 antibodies. End-point dilutions of patient CD4 T cells were performed, using virion RNA production to quantify HIV induction. Our results demonstrated that these activation approaches were not equivalent and that antibody cross-linking of CD3 and CD28 membrane receptors was the most effective means to activate HIV replication from a resting cell state, closely followed by stimulation with irradiated allogeneic cells plus PHA.

Indexed as

Lymphocyte ActivationVirus LatencyVirus ReplicationAdultAnti-HIV AgentsCD4-Positive T-LymphocytesCells, CulturedFemaleHIV-1HIV InfectionsHumansMaleVirus ActivationAnti-HIV AgentsAssay optimizationCell-associated infectious unitsHIV latencyT cell stimuli

Identifiers

PMID28527342
PMCPMC5654527
OpenAlexW2625382334

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.